✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Beryl Drugs Ltd.

BERLDRG

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹12 Cr.
P/E
53.04

Beryl Drugs Ltd.

  • Beryl Drugs
  • Parmax Pharma
  • Unjha Formulations

FAQs on Beryl Drugs Ltd. Shareprice

Beryl Drugs has given better returns compared to its competitors.
Beryl Drugs has grown at ~32.52% over the last 3yrs while peers have grown at a median rate of -2.8%

Beryl Drugs is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Beryl Drugs is 53.04, while 3 year average PE is 25.41.
Also latest EV/EBITDA of Beryl Drugs is 6.92 while 3yr average is 8.61.

View FAQ's On Business

Growth Table

  • Beryl Drugs Ltd.
  • Parmax Pharma
  • Unjha Formulations

Balance Sheet

  • Beryl Drugs Ltd.
  • Parmax Pharma
  • Unjha Formulations

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Beryl Drugs Ltd.
  • Parmax Pharma
  • Unjha Formulations

Cash Flow

  • Beryl Drugs Ltd.
  • Parmax Pharma
  • Unjha Formulations

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Beryl Drugs Ltd.
  • Parmax Pharma
  • Unjha Formulations

Quarterly Results

  • Beryl Drugs Ltd.
  • Parmax Pharma
  • Unjha Formulations

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Beryl Drugs Ltd. Financials

Balance sheet of Beryl Drugs is moderately strong.

The net debt of Beryl Drugs is decreasing.
Latest net debt of Beryl Drugs is ₹2.5 Crs as of Mar-25.
This is less than Mar-24 when it was ₹4.94 Crs.

The profit is oscillating.
The profit of Beryl Drugs is ₹0.58 Crs for Mar 2025, ₹0.77 Crs for Mar 2024 and ₹0.77 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Beryl Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech